Effectiveness of Diosmin, Cumarin and Arbutin in Reducing Edema and Pain After Hip or Knee Arthroplasty

Background/Objectives: To assess the efficacy of a product containing Diosmine, Cumarin and Arbutin (Linfadren®) in reducing edema and pain and improving specific symptomatology in patients undergoing rehabilitation treatment after hip or knee arthroplasty. Methods: In this monocentric prospective study, fifty consecutive patients, hospitalized for rehabilitation, were administered Linfadren® twice a day for 20 days. Limb circumference, pain and specific symptomatology were assessed at baseline and at the end of the treatment; the specific symptomatology was evaluated by means of the Western Ontario and McMaster Universities Arthritis Index (WOMAC), self-administered. Results: Baseline and final limb circumference showed a statistically significant difference with 60.42 ± 6.77 cm vs. 53.7 ± 6.37 cm; p < 0.0001. Baseline and final pain showed a statistically significant difference with NRS 4.0 ± 1.01 vs. 0.4 ± 0.70—p < 0.0001. Baseline and final specific symptomatology differed in a statistically significant manner with the respective scores 37.1 ± 14.4 vs. 18.1 ± 11.4; p < 0.0001. Correlations between the decrease in limb circumference, pain and specific symptomatology showed statistical significance. Conclusions: The product containing Diosmine, Cumarin and Arbutin demonstrates efficacy in reducing edema and pain and in improving specific symptomatology in patients undergoing rehabilitation treatment after hip or knee arthroplasty. This can translate to patients’ better ability to perform intensive physiotherapy protocols, thus enhancing the recovery.